- Home
- TENX
as of 12-11-2025 3:33pm EST
$9.94
+$0.12
+1.22%
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.
Chart Type:
Time Range:
| Founded: | 1967 | Country: | United States |
| Employees: | N/A | City: | CHAPEL HILL |
| Market Cap: | 56.2M | IPO Year: | N/A |
| Target Price: | $17.00 | AVG Volume (30 days): | 148.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.14 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.63 - $10.55 | Next Earning Date: | 11-12-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered TENX Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 70.00%
70.00%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Tenax Therapeutics Inc. (TENX)
Rich Stuart
Buy
Chief Medical Officer
TENX Dec 9, 2025
Avg Cost/Share
$10.22
Shares
2,500
Total Value
$25,542.00
Owned After
5,266
SEC Form 4
Rich Stuart
Buy
Chief Medical Officer
TENX Dec 8, 2025
Avg Cost/Share
$10.10
Shares
2,500
Total Value
$25,250.50
Owned After
5,266
SEC Form 4
Buy
TENX Nov 20, 2025
Avg Cost/Share
$7.59
Shares
538
Total Value
$4,082.72
Owned After
2,605
SEC Form 4
Buy
TENX Nov 19, 2025
Avg Cost/Share
$7.51
Shares
455
Total Value
$3,416.64
Owned After
2,605
SEC Form 4
Almenoff June Sherie
Buy
Director
TENX Nov 18, 2025
Avg Cost/Share
$7.52
Shares
1,900
Total Value
$14,279.83
Owned After
1,993
SEC Form 4
Buy
TENX Nov 18, 2025
Avg Cost/Share
$7.75
Shares
1,612
Total Value
$12,500.42
Owned After
2,605
SEC Form 4
Almenoff June Sherie
Buy
Director
TENX Nov 17, 2025
Avg Cost/Share
$7.15
Shares
93
Total Value
$664.95
Owned After
1,993
SEC Form 4
MCGAULEY THOMAS
Buy
Interim CFO
TENX Nov 17, 2025
Avg Cost/Share
$7.31
Shares
8,000
Total Value
$58,164.00
Owned After
2,000
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Rich Stuart | TENX | Chief Medical Officer | Dec 9, 2025 | Buy | $10.22 | 2,500 | $25,542.00 | 5,266 | |
| Rich Stuart | TENX | Chief Medical Officer | Dec 8, 2025 | Buy | $10.10 | 2,500 | $25,250.50 | 5,266 | |
| Giordano Christopher Thomas | TENX | CEO | Nov 20, 2025 | Buy | $7.59 | 538 | $4,082.72 | 2,605 | |
| Giordano Christopher Thomas | TENX | CEO | Nov 19, 2025 | Buy | $7.51 | 455 | $3,416.64 | 2,605 | |
| Almenoff June Sherie | TENX | Director | Nov 18, 2025 | Buy | $7.52 | 1,900 | $14,279.83 | 1,993 | |
| Giordano Christopher Thomas | TENX | CEO | Nov 18, 2025 | Buy | $7.75 | 1,612 | $12,500.42 | 2,605 | |
| Almenoff June Sherie | TENX | Director | Nov 17, 2025 | Buy | $7.15 | 93 | $664.95 | 1,993 | |
| MCGAULEY THOMAS | TENX | Interim CFO | Nov 17, 2025 | Buy | $7.31 | 8,000 | $58,164.00 | 2,000 |
Latest Tenax Therapeutics Inc. News
TENX Breaking Stock News: Dive into TENX Ticker-Specific Updates for Smart Investing
Compare TENX vs Leading Stocks
See how TENX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "TENX Tenax Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.